Scholarlink

<p>Tumor multidrug resistance (MDR) presents a major challenge to the efficacy of cancer chemotherapy. Pyroptosis, a form of regulated cell death distinct from apoptosis and unassociated with drug resistance, may restore tumor cells’ sensitivity to therapeutic drugs. Cinobufagin (CS-1) with efficient pyroptosis inducing capability showed the potential for the treatment of MDR cancer. However, the hydrophobic nature, low bioavailability, and possible toxic side effects under high dosage pose significant limitations on its clinical application. In this research endeavor, we have engineered a unique “chemo-gas” hybrid nanocomplexes (HA@Lip-CS-1@PBCO NPs) by wrapping CS-1 containing lipofilm onto manganese carbonyl hybrid Prussian blue nanoparticles (PBCO NPs) and modifying the targeting molecule HA on the surface. In vitro studies demonstrated that HA@Lip-CS-1@PBCO NPs, exhibiting high tumor-targeting capability, effectively induced pyroptosis in MCF-7/ADR cells through the Caspase-3/GSDME signaling pathway. In vivo assays indicated a strong inhibitory effect on MDR tumors with low CS-1 cardiotoxicity. In conclusion, this “chemo-gas” integrated therapy provides a new strategy for treating MDR tumors.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cinobufagin loaded Prussian blue-like nanoparticles for chemo/gas therapy of multidrug resistant cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月7日

查看全文
  • Wensheng Qiu,
  • Jialong Fan,
  • Weifeng Tao,
  • Jiahao Liang,
  • Chang Xiao,
  • Yi Chen,
  • Chunyi Tong,
  • Bin Liu

摘要

Tumor multidrug resistance (MDR) presents a major challenge to the efficacy of cancer chemotherapy. Pyroptosis, a form of regulated cell death distinct from apoptosis and unassociated with drug resistance, may restore tumor cells’ sensitivity to therapeutic drugs. Cinobufagin (CS-1) with efficient pyroptosis inducing capability showed the potential for the treatment of MDR cancer. However, the hydrophobic nature, low bioavailability, and possible toxic side effects under high dosage pose significant limitations on its clinical application. In this research endeavor, we have engineered a unique “chemo-gas” hybrid nanocomplexes (HA@Lip-CS-1@PBCO NPs) by wrapping CS-1 containing lipofilm onto manganese carbonyl hybrid Prussian blue nanoparticles (PBCO NPs) and modifying the targeting molecule HA on the surface. In vitro studies demonstrated that HA@Lip-CS-1@PBCO NPs, exhibiting high tumor-targeting capability, effectively induced pyroptosis in MCF-7/ADR cells through the Caspase-3/GSDME signaling pathway. In vivo assays indicated a strong inhibitory effect on MDR tumors with low CS-1 cardiotoxicity. In conclusion, this “chemo-gas” integrated therapy provides a new strategy for treating MDR tumors.

Graphical abstract